Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smoyer, W. E.
Right arrow Articles by Sherbotie, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smoyer, W. E.
Right arrow Articles by Sherbotie, J. R.

Journal of the American Society of Nephrology, Vol 6, 1401-1409, Copyright © 1995 by American Society of Nephrology


REGULAR ARTICLES

Determinants of survival in pediatric continuous hemofiltration

WE Smoyer, C McAdams, BS Kaplan and JR Sherbotie
Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, School of Medicine 19104, USA.

Continuous hemofiltration (CH) is being used in increasing numbers of pediatric intensive care unit patients. Experience with 114 CH treatments in 98 critically ill children from March 1988 to March 1993 is presented in this study. Ages ranged from 1 day to 23 yr (mean +/- SE = 7.1 +/- 0.7 yr), and 54% of patients were male. Seventeen percent of all treatments were performed in neonates under 1 month of age. The most common primary diagnoses were sepsis and adult respiratory distress syndrome (11 patients each), liver transplantation and hypoplastic left heart syndrome (10 patients each), and hemolytic uremic syndrome (9 patients). The most frequent indications for CH were fluid overload and acute renal failure (42% each). Choices for CH included: continuous arteriovenous hemofiltration (CAVH, 50%), continuous arteriovenous hemodiafiltration (CAVH, 23%), continuous venovenous hemofiltration (CVVH, 18%), and continuous venovenous hemodiafiltration (CVVH-D, 9%). Choices for anticoagulation included: none (47%), regional (49%), and systemic (4%). Treatment duration ranged from 1 to 25 days (mean = 5.3 +/- 0.4 days). Mean filter life span for 363 filters was 0.94 +/- 0.1 filters/patient per day. Despite an overall survival rate of 43%, survival to discharge varied greatly (0 to 100%) among the 24 diagnostic groups: tumor lysis syndrome and systemic lupus erythematosus (3/3 patients each, 100%), hemolytic uremic syndrome (8/9 patients, 89%). This compares with: bone marrow transplantation (0/6 patients, 0%), hypoplastic left heart syndrome (2/10 patients, 20%), and leukemia (1/4 patients, 25%). Survival to hospital discharge was better in patients who did not receive pressors (P < 0.005) and in patients treated with combined ultrafiltration and dialysis (CAVH-D, CVVH-D) compared with ultrafiltration alone (CAVH, CVVH) (P < 0.005), but was not notably affected by patient age, sex, use of anticoagulation, filter life span, blood pump-assisted versus spontaneous CH, or duration of therapy. Filter life span was not affected by use of anticoagulation, but was remarkably longer in patients with arteriovenous versus venovenous CH (P < 0.004). It was concluded that: (1) empirical anticoagulation of patients treated with CH is not necessary; (2) children with a minority of underlying diseases and those requiring pressor support at initiation of CH appear to have relatively poor survival rates despite the technically effective use of CH; and (3) the addition of countercurrent dialysis to routine CH may enhance patient survival to hospital discharge.


This article has been cited by other articles:


Home page
CJASNHome page
J. M. Symons, A. N. Chua, M. J.G. Somers, M. A. Baum, T. E. Bunchman, M. R. Benfield, P. D. Brophy, D. Blowey, J. D. Fortenberry, D. Chand, et al.
Demographic Characteristics of Pediatric Continuous Renal Replacement Therapy: A Report of the Prospective Pediatric Continuous Renal Replacement Therapy Registry
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 732 - 738.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
P. Vachvanichsanong, P. Dissaneewate, A. Lim, and E. McNeil
Childhood Acute Renal Failure: 22-Year Experience in a University Hospital in Southern Thailand
Pediatrics, September 1, 2006; 118(3): e786 - e791.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
D. M. Williams, S. S. Sreedhar, J. J. Mickell, and J. C. M. Chan
Acute Kidney Failure: A Pediatric Experience Over 20 Years
Arch Pediatr Adolesc Med, September 1, 2002; 156(9): 893 - 900.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. L. Goldstein, H. Currier, J. M. Graf, C. C. Cosio, E. D. Brewer, and R. Sachdeva
Outcome in Children Receiving Continuous Venovenous Hemofiltration
Pediatrics, June 1, 2001; 107(6): 1309 - 1312.
[Abstract] [Full Text] [PDF]


Home page
NeoReviewsHome page
P. D. Yorgin, A. Belson, and K. V. Lemley
Continuous Renal Replacement Therapy in Neonates and Young Infants
NeoReviews, September 1, 2000; 1(9): e163 - 172.
[Full Text]


Home page
NeoReviewsHome page
K. V. Lemley, S. R. Hintz, and G. M. Enns
Continuous Renal Replacement Therapy in the Initial Management of Neonatal Hyperammonemia Due to Urea Cycle Defects
NeoReviews, September 1, 2000; 1(9): e173 - 179.
[Full Text]


Home page
J CARDIOVASC PHARMACOL THERHome page
A. E. Freter, T. S. Husayni, and G. Reyes
Pharmacokinetics of Catecholamines During Hemofiltration in Pediatric Patients
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(3): 235 - 237.
[Abstract] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP